Burning Rock Biotech (NASDAQ:BNR) Announces Earnings Results

Burning Rock Biotech (NASDAQ:BNR) posted its earnings results on Thursday. The company reported ($0.21) earnings per share for the quarter, FiscalAI reports. Burning Rock Biotech had a negative net margin of 22.33% and a negative return on equity of 21.26%. The firm had revenue of $18.05 million during the quarter.

Burning Rock Biotech Price Performance

Shares of NASDAQ BNR traded down $5.25 during trading on Friday, reaching $17.60. The company had a trading volume of 32,527 shares, compared to its average volume of 25,013. The company has a current ratio of 3.14, a quick ratio of 2.91 and a debt-to-equity ratio of 0.03. Burning Rock Biotech has a twelve month low of $2.18 and a twelve month high of $41.72. The stock has a 50-day moving average price of $28.49 and a two-hundred day moving average price of $18.44. The stock has a market capitalization of $189.38 million, a PE ratio of -10.48 and a beta of 1.35.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Wall Street Zen upgraded shares of Burning Rock Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Burning Rock Biotech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BNR. Prospera Financial Services Inc purchased a new position in Burning Rock Biotech in the 3rd quarter valued at about $214,000. Crcm LP grew its holdings in shares of Burning Rock Biotech by 13.8% during the third quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after buying an additional 26,809 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Burning Rock Biotech in the fourth quarter valued at approximately $220,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Burning Rock Biotech in the third quarter valued at approximately $26,000. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.